- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00285857
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer
Studieoversigt
Detaljeret beskrivelse
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day (as 40 mg twice-a-day) would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk. Breast duct cytology was assessed as hyperplasia or hyperplasia with atypia, as measured by random periareolar fine needle aspiration (rpFNA), of breast duct cells.
A stratified analysis of this objective will be performed according to BRCA mutation status (absence or presence of an inherited deleterious BRCA1 or BRCA2 mutation).
Additional objectives of the study are to:
- Assess change in mammographic density, which is known to associate with breast cancer risk, before and after treatment with lovastatin
- Asess incidence of breast cancers and new high-risk breast lesions, including atypical hyperplasia, ductal or lobular carcinoma in situ, or radial scar.
Assess change in other breast cancer risk-associated biomarkers in rpFNA specimens, including:
- Ki-67 (a marker of cell proliferation)
- Estrogen receptor (ER)
- Progesterone receptor (PR)
- HER/2-neu over-expression
- Susceptibility to DNA damage
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
Stanford, California, Forenede Stater, 94305
- Stanford University Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
INCLUSION CRITERIA
- Female
Increased inherited risk of breast cancer, as defined by:
- Known deleterious mutation in BRCA1, BRCA2, or other high-risk mutation
- Family history conveying at least a 2-fold increase in breast cancer risk
- ECOG performance status 0
- Normal organ and marrow function, including complete blood count and comprehensive metabolic panel within normal institutional limits
- Subject agreement to limit alcoholic beverage consumption to three alcoholic drinks per week.
EXCLUSION CRITERIA
- Prior history of invasive breast cancer less than 2 years previously (EXCEPTION: stage III or lower breast cancer > 2 years ago)
- Current or history of other cancers (EXCEPTION: non-melanoma skin cancer, or stage III or cancer without evidence of recurrence for 5 years
- Initial mammogram, breast MRI, or clinical breast examination prompts recommendation for biopsy by study investigators.
- Evidence of malignant cytology on initial rpFNA.
- Use of other investigational agents.
- Use of tamoxifen or selective estrogen response modifiers (SERMS), including raloxifene, within the last 2 years.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to lovastatin.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements.
- Currently receiving lovastatin and cyclosporine, gemfibrozil, erythromycin, fibrates or niacin, (unless discontinued for study participation)
- No evidence of active liver disease, nor elevation of serum transaminases (prior history of liver disease, if not currently active, is not an exclusion)
- No evidence of myopathy or myositis, including symptoms of generalized muscle aches or weakness, muscle tenderness, or elevation in creatine phosphokinase.
- Lactating (breastfeeding)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Lovastatin 80 mg/day
Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.
|
Lovastatin 80 mg/day as 40 mg orally twice daily. Lovastatin is approved by FDA as a cholesterol-lowering agent.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in the Incidence of Abnormal Breast Duct Cytology After Treatment With Lovastatin 80 mg/Day
Tidsramme: 6 months
|
Assessed on that basis of pre- and post-treatment evaluation with RPFNA (random periareolar fine needle aspiration). All subjects received a prescription for lovastatin 80 mg/day, to be taken as 40 mg twice-a-day. Cytology was qualitatively and quantitatively, using the Masood semiquantitative scale to assign a number to each specimen, with higher numbers indicating increasing degrees of abnormality, as follows: 06-10 Non-proliferative breast disease (NPBD) 11-14 Proliferative breast disease without atypia (PBD-A) 15-18 Proliferative breast disease with atypia (PBD+A) 19-24 Carcinoma in situ and invasive cancer (CIS/IC) If no cells could be obtained after multiple RPFNA attempts, the classification was acellular. Change from NPBD to PBD-A was considered Unfavorable. Change from NPBD to Acellular was considered Equivocal. Change from PBD-A to NPBD was considered Favorable. |
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in Mammographic Density Before and After Treatment With Lovastatin 80 mg/Day
Tidsramme: 6 months
|
Bilateral mammography was performed at study entry (before lovastatin therapy) and at study conclusion (after lovastatin therapy) . Mammograms were assessed for a decline in mean breast density, using the American College of Radiology Breast Imaging Reporting and Data System (BI-RAD) composition system for mammographic density assessment. Category 0 Need additional imaging evaluation
|
6 months
|
Change in Total Cholesterol After Treatment With Lovastatin 80 mg/Day
Tidsramme: 6 months
|
6 months
|
|
Change in Low Density Lipoprotein (LDL) After Treatment With Lovastatin 80 mg/Day
Tidsramme: 6 months
|
6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: James Ford, MD, Stanford University
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hudsygdomme
- Neoplasmer
- Neoplasmer efter sted
- Brystsygdomme
- Brystneoplasmer
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antimetabolitter
- Antikolesteræmiske midler
- Hypolipidæmiske midler
- Lipidregulerende midler
- Hydroxymethylglutaryl-CoA-reduktasehæmmere
- Lovastatin
- L 647318
- Dihydromevinolin
Andre undersøgelses-id-numre
- IRB-13732
- BRSNSTU0010 (Anden identifikator: OnCore)
- 95505 (Anden identifikator: Stanford University Alternate IRB Approval Number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkendtHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
Kliniske forsøg med Lovastatin
-
Université de SherbrookeFRAXA Research FoundationAfsluttet
-
Medical University of South CarolinaAfsluttet
-
National Cancer Institute (NCI)AfsluttetPrecancerøs tilstand | Stadie II melanom | Stadie 0 melanom | Stadie I melanomForenede Stater
-
Mitchell S ElkindNational Institute of Neurological Disorders and Stroke (NINDS)AfsluttetSlag | Gulsot | RhabdomyolyseForenede Stater
-
Mutual Pharmaceutical Company, Inc.Afsluttet
-
Mutual Pharmaceutical Company, Inc.Afsluttet
-
National Heart, Lung, and Blood Institute (NHLBI)AfsluttetMyokardieiskæmi | Hjertesygdomme | Hjerte-kar-sygdomme | Koronar sygdom | Åreforkalkning | Hyperkolesterolæmi
-
Merck Sharp & Dohme LLCAfsluttetKoronararteriesygdom | ÅreforkalkningForenede Stater
-
Columbia UniversityAfsluttet
-
National Taiwan University HospitalUkendtParkinsons sygdomTaiwan